

Shared care guidelines

Drug Specialty Indication Overview Specialist's responsibilities	METHYLPHENIDATE											
	CHILDREN & YOUNG PEOPLE'S SERVICES (CYPS) ADULT MENTAL HEALTH (AMH) & LEARNING DISABILITIES (LD)											
	ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)											
	<p>Methylphenidate is an amphetamine-like drug used for the management of ADHD. It is licensed for this indication in children & adolescents but its use in adults (over 18 years) is not licensed (off-label). The management of ADHD in patients of all ages is guided by NICE NG87 (last update Sept.2019) – this guidance recommends that drug treatment:</p> <ul style="list-style-type: none"> • Is used as part of a comprehensive treatment programme addressing psychological, behavioural and educational/occupational needs; • Is used for children aged 5 years & over & young people only if their ADHD symptoms are still causing a persistent significant impairment in at least one domain after environmental modifications have been implemented & reviewed; they & their parents & carers have discussed information about ADHD & a baseline assessment has been carried out. • Is used in adults (over 18 years) if their ADHD symptoms are still causing a significant impairment in at least one domain after environmental modifications have been implemented & reviewed unless the person has made an informed choice not to have medication, has difficulty adhering to medication or found medication ineffective or cannot tolerate it. • Is initiated only by an expert in ADHD, but prescribing & monitoring responsibility can transfer to GPs under shared care arrangements. <p>Drug treatment of ADHD in patients under the care of TEWV is guided by separate prescribing algorithms for children & adolescents and adults (<i>Intranet – keyword ADHD, Trust website</i>)</p>											
	<p>Pre-treatment assessment (see SPC for contra-indications):</p> <ul style="list-style-type: none"> • Full mental health and social assessment, including risk assessment for substance misuse and drug diversion; • Evaluation of cardiovascular status, including: <ul style="list-style-type: none"> ○ Heart rate & BP - plotted on a centile chart [refer to paediatric hypertension specialist before starting treatment if BP is consistently above 95th centile] ○ ECG, and refer for cardiology opinion before starting treatment, if there is: <ul style="list-style-type: none"> ▪ history of congenital heart disease or previous cardiac surgery ▪ history of sudden death in a first-degree relative under 40 years suggesting a cardiac disease ▪ shortness of breath on exertion compared with peers ▪ fainting on exertion or in response to fright or noise ▪ palpitations that are rapid, regular and start and stop suddenly ▪ chest pain suggesting cardiac origin ▪ signs of heart failure ▪ a murmur heard on cardiac examination ▪ BP that is classified as hypertensive in adults <p>[ECG is not needed if all of the above are absent and the person is not taking medication that poses an increased cardiac risk]</p> • Height (children & adolescents only) & weight – plotted on a growth chart <p>Initiation and titration of drug treatment:</p> <ul style="list-style-type: none"> • Issue patient with ADHD medication treatment booklet, and complete essential details • Prescribe methylphenidate during dose titration until the patient is stabilised, has had a 3 month check and shared care has been formally accepted by the patient's GP / primary care team. <p><i>Ritalin® / generic immediate-release preps:</i> Children (6-17 years): 5 mg 1-2 times daily, increased if necessary at weekly intervals by 5-10 mg daily Adults: 5 mg twice daily, increased if necessary at weekly intervals by 5-10 mg daily</p> <p><i>Concerta® XL / Matoride XL / Xenidate XL / Delmosart / Xaggitin XL:</i> Children & Adults – 18 mg once daily, increased if necessary at weekly intervals by 18 mg daily</p> <p><i>Equasym XL® / Medikinet XL®:</i> Children & Adults – 10 mg once daily, increased if necessary at weekly intervals by 10 mg daily</p>											
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left;">Drug / preparation</th> <th style="text-align: left;">Licensed maximum dose</th> <th style="text-align: left;">Off-label maximum dose (specialist direction only)</th> </tr> </thead> <tbody> <tr> <td>Methylphenidate immediate-release</td> <td>Children*: 60 mg / day**</td> <td>Children*: 90 mg / day** Adults: 100 mg / day**</td> </tr> <tr> <td>Concerta XL, Xenidate XL, Matoride XL, Delmosart, Xaggitin XL</td> <td>Children*: 54 mg / day**</td> <td>Children* & Adults: 108 mg / day**</td> </tr> <tr> <td>Equasym XL, Medikinet XL</td> <td>Children*: 60 mg / day</td> <td>Children*: 90 mg / day Adults: 100 mg / day</td> </tr> </tbody> </table>	Drug / preparation	Licensed maximum dose	Off-label maximum dose (specialist direction only)	Methylphenidate immediate-release	Children*: 60 mg / day**	Children*: 90 mg / day** Adults: 100 mg / day**	Concerta XL, Xenidate XL, Matoride XL, Delmosart, Xaggitin XL	Children*: 54 mg / day**	Children* & Adults: 108 mg / day**	Equasym XL, Medikinet XL	Children*: 60 mg / day	Children*: 90 mg / day Adults: 100 mg / day
Drug / preparation	Licensed maximum dose	Off-label maximum dose (specialist direction only)										
Methylphenidate immediate-release	Children*: 60 mg / day**	Children*: 90 mg / day** Adults: 100 mg / day**										
Concerta XL, Xenidate XL, Matoride XL, Delmosart, Xaggitin XL	Children*: 54 mg / day**	Children* & Adults: 108 mg / day**										
Equasym XL, Medikinet XL	Children*: 60 mg / day	Children*: 90 mg / day Adults: 100 mg / day										

* 6-17 years **for total dose calculation in mixed IR/XL treatment, 15 mg IR = 18 mg as Concerta XL or equivalent product

Title	Shared Care Guidelines - Methylphenidate		
Approved by	Drug & Therapeutics Committee	Date of Approval	25 th March 2021
Protocol Number	PHARM-0027-v5	Date of Review	1 st April 2025 (extended)

Specialist's responsibilities (continued)

Clinical monitoring:

- Assess response to treatment and need for dose adjustment every month until stabilised. Discontinue and consider alternatives if no response after 1 month.
- If treatment continues, re-assess at least annually & consider interrupting treatment to determine whether continuation is necessary.
- Adolescents - if still on treatment at school-leaving age, determine if treatment needs to be continued &, if it does, arrange transition to AMH / LD services by 18 years of age.
- Consider monitoring BMI of adults with ADHD if there has been weight change as a result of their treatment and changing the medication if weight change persists

Safety monitoring:

- Cardiovascular status - check heart rate & BP at each dose change, and at each face-to-face review if >6 months since last check by team or GP – record on centile charts to detect clinically important changes
- Height (children & young people only) – at each face-to-face review if >6 months since last check by team or GP – record on growth chart
- Weight – within 3 months (prior to transfer) in children and young people; at each face-to-face review if >3 months (children 10 years & under) or >6 months (children >10 years & adults) since last check by team or GP, more often if concerns arise – record on growth chart
- Routine blood tests and ECGs are not required unless there is a clinical indication

Transfer of prescribing:

- Request transfer of prescribing and monitoring under shared care arrangements on an individual patient basis using the attached standard form with a covering clinic letter
- Provide a point of contact during working hours for any queries related to the prescribing and monitoring of methylphenidate
- If patient transferring from C&YPS to AMH / LD service, notify GP of new TEWV team details and arrangements for review. Existing shared care arrangements should not be interrupted.

Documentation & communication:

- At each review, update growth / centile charts and patient-held ADHD medication booklet with monitoring checks and dose changes
- After each review, send comprehensive letter to GP detailing outcome of review, date and outcome of monitoring (BP & pulse), changes to medication and plans for further review.
- Notify the GP and primary care team if the patient does not attend for specialist reviews

GP's responsibilities

- Acknowledge and respond to the request for shared care within 2 weeks of receipt
- Contact specialist if communication of prescribing & monitoring requirements is not clear
- Add methylphenidate to the patient's repeat prescription (even if not yet prescribing) so that drug interactions will be highlighted by the clinical system
- Provide regular, repeat prescriptions for methylphenidate (as the brand name for extended-release products) at dosage recommended by the specialist team (see above for usual maintenance and maximum doses)
- Limit prescriptions to 28 days' supply per prescription, in line with good practice relating to controlled drugs
- Assess cardiovascular status (heart rate & BP) every 6 months unless notified that done at review by specialist team – record on centile charts for children & young people to detect clinically important changes
- Measure height (children & adolescents only) every 6 months & weight every 3 months (children 10 years & under) or every 6 months (children >10 years & adults) unless notified that done at review by specialist team; more often if concerns arise – record on growth chart
- Be aware of potential side effects and inform the specialist team of suspected side effects
- Seek advice from the specialist team if the patient becomes clinically unstable
- Notify the specialist team of any change in the patient's physical health or social circumstances which may impact on or preclude treatment with methylphenidate (e.g. illicit drug misuse)
- Check review by specialist has taken place within last 12 months
- Stop issuing prescriptions if notified by the specialist team

Adverse events

Adverse event	Action (GP)	Action (specialist)
Raised BP (systolic BP > 95 th centile or clinically significant increase) or pulse > 120 bpm resting) or arrhythmia	Notify & seek advice from specialist	Reduce dose & seek advice from paediatrician or cardiologist
Signs / symptoms of heart disease		Reduce dose, or switch to alternative drug
Reduced rate of growth (height or weight)		Stop treatment & perform full psychiatric assessment
Signs / symptoms of psychiatric disorder		

Other information

Treatment of ADHD in people with a dual diagnosis (psychiatric disorder & substance dependence) should only be prescribed by healthcare professionals with expertise in managing both ADHD & substance misuse or direct access to substance misuse teams. For adults with ADHD & drug or alcohol disorders there should be close liaison with addiction services, & close monitoring of any interventions

Title	Shared Care Guidelines - Methylphenidate		
Approved by	Drug & Therapeutics Committee	Date of Approval	25 th March 2021
Protocol Number	PHARM-0027-v5	Date of Review	1 st April 2025 (extended)

AMBER ▲	REQUEST FOR SHARED CARE (TRANSFER OF PRESCRIBING) OF MEDICINES FOR ADHD		
GP details:			
Patient details (name/address/DOB/NHS number):			
Diagnosis:			
Medication details (list dose, frequency and brand if appropriate. Specify clinical indications if first line option not prescribed or non-standard formulation prescribed) The patient is stabilised on:			
Discontinued medication (list details of any drugs discontinued when this AMBER treatment initiated):			
Last prescription issued (details of date and length of supply):			
Monitoring results to date:			
Planned specialist review:			
Actions requested of GP: Please continue to issue monthly (28 days) prescriptions until advised otherwise The treatment has been explained to the patient and they understand they should contact you for future prescriptions. You will be informed of any changes to treatment, if you are not required to issue prescriptions or if treatment is to be discontinued. Please contact the prescriber on the number below if there is any change in the patient's condition or social circumstances, if the patient fails to regularly collect prescriptions, if non-compliance with treatment is suspected or you require any other advice.			
Specialist team contacts:		Contact details (e-mail/telephone no):	
Care coordinator (name):			
Consultant (name):			
Prescriber (name):			
Signature:		Date:	

Title	Shared Care Guidelines - Methylphenidate		
Approved by	Drug & Therapeutics Committee	Date of Approval	25 th March 2021
Protocol Number	PHARM-0027-v5	Date of Review	1 st April 2025 (extended)

Acceptance of shared care for ADHD medication

Patient's name:	NHS Number:
Address:	
Medication:	
I confirm receipt of prescribing transfer information for the above patient and accept my responsibilities within the agreed shared care arrangements	
GP name: <i>(Please print name in BLOCK CAPITALS)</i>	
Signature/ Practice Stamp:	
Date:	

Please scan & e-mail back to:
E-mail:
or return by post as soon as possible to:

Title	Shared Care Guidelines - Methylphenidate		
Approved by	Drug & Therapeutics Committee	Date of Approval	25 th March 2021
Protocol Number	PHARM-0027-v5	Date of Review	1 st April 2025 (extended)